Key Points
Superstring Capital Management reduced its stake in Terns by 345,869 shares during the fourth quarter; the estimated trade value was $7.99 million based on quarterly average prices.
Meanwhile, the quarter-end position value declined by approximately $12.00 million, reflecting both trading and stock price movements.
The post-transaction holding stood at 443,777 shares valued at $17.93 million, per an SEC filing.
On February 17, 2026, Superstring Capital Management reported selling 345,869 shares of Terns Pharmaceuticals(NASDAQ:TERN) in the fourth quarter, an estimated $7.99 million trade based on quarterly average pricing.
What happened
According to a February 17, 2026, SEC filing, Superstring Capital Management reduced its position in Terns Pharmaceuticals by 345,869 shares during the fourth quarter of 2025. The estimated value of the trade, derived from the average closing price for the quarter, was $7.99 million. The fund’s quarter-end position in Terns Pharmaceuticals decreased in value by approximately $12.00 million, reflecting both share sales and stock price moves.
What else to know
- Top holdings after the filing:
- NASDAQ:CDTX: $18.80 million (10.1% of AUM)
- NASDAQ:TERN: $17.93 million (9.6% of AUM)
- NASDAQ:URGN: $16.82 million (9.0% of AUM)
- NASDAQ:COGT: $13.01 million (7.0% of AUM)
- NASDAQ:DVAX: $8.08 million (4.3% of AUM)
- As of Wednesday, Terns shares were priced at $45.56, up a staggering 1,300% over the past year and vastly outperforming the S&P 500’s roughly 19% gain in the same period.
Company overview
| Metric | Value |
|---|---|
| Price (as of Wednesday) | $45.56 |
| Market capitalization | $4.9 billion |
| Net income (TTM) | ($94.44 million) |
Company snapshot
- Terns develops small-molecule therapies targeting chronic myeloid leukemia (CML), non-alcoholic steatohepatitis (NASH) and obesity, with lead candidates including TERN-101, TERN-201, TERN-501, and TERN-601 in various stages of clinical development.
- The firm operates a clinical-stage biopharmaceutical business model focused on advancing proprietary drug candidates through early- and mid-stage trials, aiming for eventual regulatory approval and commercialization or strategic partnerships.
- It has targeted patients with NASH and metabolic diseases, addressing unmet needs in the global healthcare and biotechnology markets.
What this transaction means for investors
Even after trimming Terns, the stock remains one of the largest holdings in Superstring’s portfolio, which tells you this is not a loss of conviction but a recalibration after an extraordinary move.
A 1,300% gain in a single year is staggering, and it certainly creates some expectations, which matter in biotech, where outcomes hinge on trial execution and regulatory milestones rather than steady revenue growth.
The underlying story, however, is still compelling. Terns has repositioned around oncology, with its lead program for chronic myeloid leukemia showing strong early efficacy and a slate of catalysts expected this year, including dose selection and pivotal trial progress. Meanwhile, roughly $1 billion in cash provides runway into 2031, reducing the firm’s near-term financing risk thanks largely to a massive $747.5 million offering in December. If catalysts deliver positive results and Terns can launch its inhibitor by 2031, the recent share surge might prove to have legs.
Should you buy stock in Terns Pharmaceuticals right now?
Before you buy stock in Terns Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Terns Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $508,877!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,115,328!*
Now, it’s worth noting Stock Advisor’s total average return is 936% — a market-crushing outperformance compared to 189% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 18, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
